Clinical Trials on Castrate Resistent Prostate Cancer in New Zealand

Total 1109 results

Sidney Kimmel Cancer Center at Thomas Jefferson...
Novartis Pharmaceuticals

Terminated

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Prostate Cancer | Castrate Resistant Prostate Cancer | Chemotherapy Naive Prostate Cancer

United States
Hoffmann-La Roche

Completed

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Castrate-Resistant Prostate Cancer

United States
Exosome Diagnostics, Inc.
Yale University

Suspended

Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)

Metastatic Castrate Resistant Prostate Cancer

United States
Suzhou Kintor Pharmaceutical Inc,

Completed

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

United States
Royal North Shore Hospital

Terminated

Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer

Metastatic Castrate- Resistant Prostate Cancer

Australia
Effector Therapeutics

Completed

An Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)

Castrate-resistant Prostate Cancer (CRPC)

United States
Tracon Pharmaceuticals Inc.
Janssen Pharmaceutica N.V., Belgium

Completed

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Metastatic Castrate-resistant Prostate Cancer | Adenocarcinoma, Prostate

United States
Amgen

Completed

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Carcinoma | Cancer | Prostate Cancer | Tumors | Castrate-Resistant Prostate Cancer

United States, Canada, Poland, Hungary, Finland, Mexico
Costantine Albany
Hoosier Cancer Research Network; Achieve Life Sciences

Terminated

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Prostate Cancer | PSA | Metastatic Castrate-Resistant Prostate Cancer

United States, Canada
Achieve Life Sciences
Teva Pharmaceuticals USA

Terminated

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Hormone Refractory Prostate Cancer | Castrate-Resistant Prostate Cancer

France, United States, Spain, United Kingdom, Canada
Trans Tasman Radiation Oncology Group
Bayer; Peter MacCallum Cancer Centre, Australia

Recruiting

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA (DECREASE)

Advanced Prostate Carcinoma | Castrate Resistant Prostate Cancer | Cancer of Prostate | PSA

Australia, Singapore
Suzhou Kintor Pharmaceutical Inc,

Completed

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Metastatic Castrate Resistant Prostate Cancer (mCRPC)

United States
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Castrate-Resistant Prostate Cancer

United States, Puerto Rico, Hungary, Romania, Russian Federation, Poland
AstraZeneca

Completed

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer. (PYRUS)

Metastatic Castrate-Resistant Prostate Cancer (mCRPC), | Efficacy, | Safety and Tolerability, | Pharmacokinetics, | Pharmacodynamics, | Tumour Response.

United Kingdom, United States
Bayer

Recruiting

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Hong Kong, Spain, Taiwan, Australia, Turkey, France, Germany, Hungary, United Kingdom, Singapore, Korea, Republic of, Czechia, Italy, Finland, Israel, Austria, Lithuania, Poland, Russian Federation
Janux Therapeutics

Recruiting

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic Cancer

United States, Australia
Nuvation Bio Inc.

Recruiting

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Breast Carcinoma | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Cancer of the Ovary | Pancreas Cancer | Triple-negative Breast Cancer | Cancer of Pancreas | Pancreas Neoplasm | Prostate Neoplasm | Cancer... and other conditions

United States, Australia
OHSU Knight Cancer Institute
Bristol-Myers Squibb; Oregon Health and Science University

Completed

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
VA Office of Research and Development

Recruiting

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer (COBRA)

Metastatic Castrate Resistant Prostate Cancer | BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2 | RAD51B, RAD51C, RAD51D, or RAD54L Mutations

United States
Nuvation Bio Inc.

Terminated

Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

Glioma | Breast Cancer | Glioblastoma | Advanced Breast Cancer | Prostate Cancer | Metastatic Breast Cancer | Recurrent Glioblastoma | Breast Carcinoma | Castration-resistant Prostate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Glioma, Malignant | Cancer of Breast | Malignant Tumor of Breast and other conditions

United States
Myovant Sciences GmbH

Recruiting

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate Cancer

United States
Veru Inc.

Terminated

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent (VERACITY)

Metastatic Castration-resistant Prostate Cancer | Androgen Resistant Prostatic Cancer

United States
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC

Terminated

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

Metastatic Castration-Resistant Prostate Cancer

United States
Tulane University
Blue Earth Diagnostics

Completed

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

Metastatic Castration-resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Terminated

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer (ASPIRE-PCa)

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Prostate Cancer

Spain, Taiwan, France, Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, Germany, Indonesia, Israel, Italy, Korea, Republic of, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Sin... and more
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

Castration Resistant Prostate Cancer | Prostate Carcinoma Metastatic to the Bone

United States
National Cancer Institute (NCI)

Completed

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Jodi Layton, MD
EMD Serono

Terminated

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Metastatic Castration-resistant Prostate Cancer

United States
Bayer

Completed

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). (PHENIX)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Completed

Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Bayer

Completed

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo) (EPIX)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
St Vincent's Hospital, Sydney

Recruiting

Bipolar Androgen Therapy + Carboplatin in mCRPC (HiTeCH)

Castration-resistant Prostate Cancer | Homologous Recombination Deficiency

Australia
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate Neoplasm

United States
Memorial Sloan Kettering Cancer Center
Celgene Corporation

Completed

Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer

Prostate Cancer | Castration Resistant Prostate Cancer

United States
University of Alabama at Birmingham
Amgen

Completed

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

Metastatic Castration-resistant Prostate Cancer

United States
Roswell Park Cancer Institute
Dendreon

Completed

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

Metastatic Malignant Neoplasm in the Bone | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Dizal Pharmaceuticals

Terminated

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

Metastatic Castration Resistant Prostate Cancer

United States, Korea, Republic of
Lava Therapeutics

Recruiting

Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

United States
Promontory Therapeutics Inc.

Active, not recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Urogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Advanced Solid Tumors | mCRPC | Metastatic Castrate-resistant Prostate Cancer | CRPC | PT-112

United States, France
Sidney Kimmel Comprehensive Cancer Center at Johns...
United States Department of Defense

Completed

Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance (Transformer)

Castration Resistant Metastatic Prostate Cancer

United States
Dendreon

Completed

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

Hormone Refractory Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

United States
Bayer

Completed

Multi-academic Center Study of Xofigo Patients

Prostate Cancer, Castration Resistant

United States
Janssen Research & Development, LLC

Recruiting

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC (LIBERTAS)

Metastatic Castrate-sensitive Prostate Cancer

United States, France, Mexico, Germany, Australia, Brazil, Canada, China, Poland
Astellas Pharma Global Development, Inc.
Medivation, Inc.

Terminated

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

Metastatic Castration Resistant Prostate Cancer

United States
Roswell Park Cancer Institute
Active Biotech AB

Completed

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States

Clinical Trials on Castrate Resistent Prostate Cancer in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations